Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H14O6 |
| Molecular Weight | 218.2039 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCC(COC(C)=O)OC(C)=O
InChI
InChIKey=URAYPUMNDPQOKB-UHFFFAOYSA-N
InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3
| Molecular Formula | C9H14O6 |
| Molecular Weight | 218.2039 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050808lbl.pdf; http://www.ncbi.nlm.nih.gov/pubmed/?term=20800682; http://www.inchem.org/documents/sids/sids/102761.pdf;
Curator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050808lbl.pdf; http://www.ncbi.nlm.nih.gov/pubmed/?term=20800682; http://www.inchem.org/documents/sids/sids/102761.pdf;
Triacetin, also known as Glyceryl Triacetate, is a cosmetic biocide, plasticizer, and solvent in cosmetic formulations, at concentrations ranging from 0.8% to 4.0%. It is a commonly used carrier for flavors and fragrances. Triacetin was affirmed as a generally recognized as safe (GRAS) human food ingredient by the Food and Drug Administration (FDA). It is used as an inactive ingredient additive in some drug formulations. It has been used as a plasticizer in the tests of acrylic polymer films for drug delivery. Triacetin is not toxic to animals. However, in one study, it caused erythema, slight edema, alopecia, and desquamation, and did cause some irritation in rabbit eyes. Concentration of triacetin in consumer products is in the range of about 0.005-2 % for cosmetics, and has been reported to be as high as 15-33 % for one specific antifungal drug.
CNS Activity
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | Bupropion Approved UseBupropion hydrochloride extended-release tablets (XL) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of Bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of Bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to Bupropion in an 8-week study of acute treatment. Launch Date1985 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
50 % single, topical Studied dose Dose: 50 % Route: topical Route: single Dose: 50 % Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
Other AEs: Skin irritation... Other AEs: Skin irritation (grade 1) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Skin irritation | grade 1 | 50 % single, topical Studied dose Dose: 50 % Route: topical Route: single Dose: 50 % Sources: |
healthy, adult Health Status: healthy Age Group: adult Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Induction of CCAAT/enhancer-binding protein-homologous protein by cigarette smoke through the superoxide anion-triggered PERK-eIF2α pathway. | 2011-09-05 |
|
| Phospholipids-embedded fully dilutable liquid nanostructures. Part 2: The role of sodium diclofenac. | 2010-12-01 |
|
| Wavelet analysis used for spectral background removal in the determination of glucose from near-infrared single-beam spectra. | 2010-11-29 |
|
| The use of dynamic mechanical analysis (DMA) to evaluate plasticization of acrylic polymer films under simulated gastrointestinal conditions. | 2010-11 |
|
| Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery. | 2010-11 |
|
| Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. | 2010-10 |
|
| In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants. | 2010-09-15 |
|
| Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. | 2010-06 |
|
| Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine. | 2010-03-19 |
|
| Glycerol triacetate as solvent and acyl donor in the production of isoamyl acetate with Candida antarctica lipase B. | 2010-03 |
|
| A glycerol-free process to produce biodiesel by supercritical methyl acetate technology: an optimization study via Response Surface Methodology. | 2010-02 |
|
| Metabolic acetate therapy for the treatment of traumatic brain injury. | 2010-01 |
|
| Stability of citral in oil-in-water emulsions prepared with medium-chain triacylglycerols and triacetin. | 2009-12-09 |
|
| Criterion for excipients screening in the development of nanoemulsion formulation of three anti-inflammatory drugs. | 2009-11-17 |
|
| Phospholipids embedded fully dilutable liquid nanostructures. Part 1: compositions and solubilization capacity. | 2009-10-01 |
|
| Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model. | 2009-10 |
|
| Thermostable lipases from the extreme thermophilic anaerobic bacteria Thermoanaerobacter thermohydrosulfuricus SOL1 and Caldanaerobacter subterraneus subsp. tengcongensis. | 2009-09 |
|
| Formation and characterization of ordered bicontinuous microemulsions. | 2009-08-06 |
|
| Evaluation of the mechanical properties and drug release of cross-linked Eudragit films containing metronidazole. | 2009-07-06 |
|
| In situ forming polymeric drug delivery systems. | 2009-05 |
|
| Spectral simulation protocol for extending the lifetime of near-infrared multivariate calibrations. | 2009-02-01 |
|
| Hookah (Shisha, Narghile) Smoking and Environmental Tobacco Smoke (ETS). A critical review of the relevant literature and the public health consequences. | 2009-02 |
|
| Digital filtering and model updating methods for improving the robustness of near-infrared multivariate calibrations. | 2009-02 |
|
| Refeeding syndrome--awareness, prevention and management. | 2009-01-26 |
|
| Transdermal delivery of salbutamol sulphate: formulation and evaluation. | 2009 |
|
| Determination of the composition of acetylglycerol mixtures by (1)H NMR followed by GC investigation. | 2008-11-15 |
|
| Viability and permeability across Caco-2 cells of CBZ solubilized in fully dilutable microemulsions. | 2008-10-01 |
|
| Influence of plasticizers on the stability and release of a prodrug of Delta(9)-tetrahydrocannabinol incorporated in poly (ethylene oxide) matrices. | 2008-10 |
|
| Template enhanced activity of lipase accommodated in siliceous mesocellular foams. | 2008-08-08 |
|
| Transdermal patch incorporating salbutamol sulphate: In vitro and clinical characterization. | 2008-08 |
|
| Skin permeation mechanism of aceclofenac using novel nanoemulsion formulation. | 2008-08 |
|
| Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. | 2008-07-09 |
|
| In vitro and in vivo transdermal studies of atenolol using iontophoresis. | 2008-06-10 |
|
| Influence of flavor solvent on flavor release and perception in sugar-free chewing gum. | 2008-05-14 |
|
| Formulation design of taste-masked particles, including famotidine, for an oral fast-disintegrating dosage form. | 2008-04 |
|
| Understanding structural features of microbial lipases--an overview. | 2008-03-27 |
|
| A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. | 2008-03-10 |
|
| A potential high-throughput method for the determination of lipase activity by potentiometric flow injection titrations. | 2008-03-03 |
|
| Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. | 2008-03-03 |
|
| Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. | 2008-02-02 |
|
| Photoinduced intramolecular charge transfer in push-pull polyenes: effects of solvation, electron-donor group, and polyenic chain length. | 2008-01-17 |
|
| Design and characterization of an adhesive matrix based on a poly(ethyl acrylate, methyl methacrylate). | 2008 |
|
| A squeeze-type osmotic tablet for controlled delivery of nifedipine. | 2008 |
|
| Nanoemulsions as vehicles for transdermal delivery of aceclofenac. | 2007-12-14 |
|
| Modulation of a pulsatile release drug delivery system using different swellable/rupturable materials. | 2007-11 |
|
| Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. | 2007-09 |
|
| Abstracts of papers presented at the 2007 pittsburgh conference. | 2007 |
|
| Emissions from cooking microwave popcorn. | 2007 |
|
| Controlled release multiparticulate beads coated with starch acetate: material characterization, and identification of critical formulation and process variables. | 2007 |
|
| Transdermal oxybutynin in the treatment of overactive bladder. | 2006 |
Patents
Sample Use Guides
In Vitro Use Guide
Curator's Comment: When triacetin was incubated with the sacs of rats everted intestine, the glyceride entered the epithelial cells and was completely hydrolyzed to free glycerol and acetic acid. Triacetin released 307 ± 11 umoles of acetate. With increasing concentrations of glyceride (5, 10 and 15 mM), the amount of acetate released increased linearly up to about a total amount of 300 umoles of acetate released.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 06:51:52 GMT 2025
by
admin
on
Wed Apr 02 06:51:52 GMT 2025
|
| Record UNII |
XHX3C3X673
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1697
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
||
|
JECFA EVALUATION |
INS-1518
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-1518
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
||
|
CFR |
21 CFR 175.320
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
||
|
CFR |
21 CFR 184.1901
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XHX3C3X673
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
XHX3C3X673
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
C82268
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
TRIACETIN
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
3624
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
SUB11249MIG
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
102-76-1
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
731
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
836
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
m11021
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
1675007
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
203-051-9
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
9661
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
4796
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
10756
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL1489254
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
DTXSID3026691
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
100000077489
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
5541
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY | |||
|
585
Created by
admin on Wed Apr 02 06:51:52 GMT 2025 , Edited by admin on Wed Apr 02 06:51:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Triacetine (ug/cigarette)
Canadian = 23.1 SD(15.6)
Imported = 36.3 SD(9.3)
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
